# A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

> **NCT06199336** · PHASE1,PHASE2 · COMPLETED · sponsor: **JHM BioPharma (Tonghua) Co. , Ltd.** · enrollment: 190 (actual)

## Conditions studied

- Moderate to Severe Glabellar Lines

## Interventions

- **BIOLOGICAL:** JHM03
- **BIOLOGICAL:** BOTOX®
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06199336
- **Lead sponsor:** JHM BioPharma (Tonghua) Co. , Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-19
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199336, "A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT06199336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*